- Home
- SMCI vs RPRX Comparison
SMCI vs RPRX Comparison
Compare SMCI & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SMCI | RPRX |
|---|---|---|
| Founded | 1993 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.4B | 16.4B |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SMCI | RPRX |
|---|---|---|
| Price | $32.66 | $39.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 4 |
| Target Price | $44.35 | ★ $45.75 |
| AVG Volume (30 Days) | ★ 28.8M | 3.3M |
| Earning Date | 02-10-2026 | 02-10-2026 |
| Dividend Yield | N/A | ★ 2.38% |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.26 | ★ 1.75 |
| Revenue | ★ $21,052,576,000.00 | $2,349,844,000.00 |
| Revenue This Year | $67.33 | $37.66 |
| Revenue Next Year | $21.98 | $2.34 |
| P/E Ratio | $25.97 | ★ $22.58 |
| Revenue Growth | ★ 11.94 | 3.70 |
| 52 Week Low | $25.71 | $29.66 |
| 52 Week High | $66.44 | $41.70 |
Technical Indicators
Market Signals| Indicator | SMCI | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.19 | 49.50 |
| Support Level | $27.75 | $39.87 |
| Resistance Level | $31.03 | $40.58 |
| Average True Range (ATR) | 1.36 | 0.78 |
| MACD | 0.41 | -0.03 |
| Stochastic Oscillator | 97.04 | 34.46 |
Price Performance
Historical ComparisonAbout SMCI Super Micro Computer Inc.
Super Micro Computer Inc provides high-performance server technology services to cloud computing, data centers, high-performance computing, and the Internet of Things embedded markets. Its solutions include servers, storage systems, modular blade servers, workstations, full-rack scale solutions, networking devices, server sub-systems, and server management. These turn-key solutions are designed, developed, validated, and installed for AI datacenters. The company has one operating segment that develops and provides high-performance server solutions based upon a, modular and open-standard architecture. More than half of the firm's revenue is generated in the United States, with the rest coming from Europe, Asia, and other regions.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.